John Jason Fallows: October 2018

Wednesday, October 31, 2018

New cancer clinical trial: Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Published on: October 30, 2018 at 12:00PM
Condition: Breast Cancer
Interventions: Biological: Pembrolizumab (K); Drug: Placebo (P); Drug: Paclitaxel (X); Drug: Doxorubicin hydrochloride (A); Drug: Epirubicin (E); Drug: Cyclophosphamide (C); Drug: Endocrine therapy; Radiation: Radiation therapy; Procedure: Surgery
Sponsor: Merck Sharp & Dohme Corp.
Not yet recruiting
https://ift.tt/2Q8FkVi

New cancer clinical trial: Identification of Molecular Biomarkers for Cancer Target Therapy Efficacy

Published on: October 30, 2018 at 12:00PM
Condition: Cancer
Interventions: Other: RNA sequencing; Other: Transcriptome analysis; Drug: target drug with the score above 0,1; Drug: target drug with the score equal or below 0,1; Drug: non-target drug; Drug: palliative care
Sponsors: OmicsWay Corp.; Oncobox Ltd; Vitamed LLC; N.N. Blokhin National Medical Research Center of Oncology; Kaluga Regional Clinical Oncology Center; Multidisciplinary medical holding SM-Clinic; Oncological Clinical Dispensary No. 1 of the Moscow City Health Department
Recruiting
https://ift.tt/2qin3K1

New cancer clinical trial: Chemotherapy, Host Response and Molecular Dynamics in Periampullary Cancer

Published on: October 30, 2018 at 12:00PM
Conditions: Periampullary Adenocarcinoma; Periampullary Cancer; Pancreatic Cancer
Intervention: Drug: Gemcitabine
Sponsor: Lund University
Recruiting
https://ift.tt/2Q78KDj

New cancer clinical trial: Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Metastatic Castration Resistant Prostate Cancer

Published on: October 30, 2018 at 12:00PM
Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
Intervention: Drug: BAY 2315497 Injection
Sponsor: Bayer
Not yet recruiting
https://ift.tt/2qimYWJ

New cancer clinical trial: Occupational Therapist-Led Work Intervention in Facilitating Work Maintenance or Re-entry to the Workforce in Patients With Stage I to III Breast Cancer Undergoing Chemotherapy

Published on: October 30, 2018 at 12:00PM
Conditions: Breast Cancer Stage I; Breast Cancer Stage III; Breast Cancer Stage II; Breast Cancer Stage IIA; Breast Cancer Stage IIB; Breast Cancer Stage IIIA; Breast Cancer Stage IIIB; Breast Cancer Stage IIIc; Breast Cancer
Interventions: Behavioral: Occupational Therapy; Other: Questionnaire Administration; Other: Quality-of-Life Assessment
Sponsor: University of Washington
Not yet recruiting
https://ift.tt/2Q7mYEk

New cancer clinical trial: Pembrolizumab and Pelareorep in Treating Patients With Advanced Pancreatic Cancer

Published on: October 30, 2018 at 12:00PM
Conditions: Pancreatic Adenocarcinoma; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8
Interventions: Biological: Pembrolizumab; Biological: Wild-type Reovirus
Sponsors: Northwestern University; National Cancer Institute (NCI)
Not yet recruiting
https://ift.tt/2qimVdv

New cancer clinical trial: [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)

Published on: October 30, 2018 at 12:00PM
Conditions: Breast Cancer; Prostate Cancer; Colorectal Cancer; Non Small Cell Lung Cancer; Small Cell Lung Cancer
Intervention: Drug: [68Ga]-NeoBOMB1
Sponsor: Advanced Accelerator Applications
Recruiting
https://ift.tt/2Q4PTsB

New cancer clinical trial: Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

Published on: October 30, 2018 at 12:00PM
Condition: Neuroendocrine Tumors
Intervention: Drug: [90]Y-DOTATOC
Sponsors: Sandeep Laroia; National Institutes of Health (NIH); Holden Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting
https://ift.tt/2qimPm9

New cancer clinical trial: NSE/Alb as a Prognostic Biomarker for Lung Cancer

Published on: October 30, 2018 at 12:00PM
Condition: Carcinoma, Non-Small-Cell Lung
Intervention: Diagnostic Test: Neuron-Specific Enolase to Albumin Ratio
Sponsors: First Affiliated Hospital Xi'an Jiaotong University; Second Affiliated Hospital of Xi'an Jiaotong University; Shaanxi Provincial Cancer Hospital; Shaanxi Provincial People's Hospital; Xi'an Central Hospital
Recruiting
https://ift.tt/2Q9wAhF

New cancer clinical trial: Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.

Published on: October 30, 2018 at 12:00PM
Conditions: Colon Cancer; Digestive System Neoplasm
Interventions: Biological: TG6002; Drug: Flucytosine (5-FC, Ancotil)
Sponsor: Transgene
Recruiting
https://ift.tt/2qihtXU